3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
2
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Leiomyosarcoma
1
Inflammation
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Interventions
Doxorubicin
6
Ifosfamide
5
Radiotherapy
4
pazopanib
3
cediranib
3
atezolizumab
3
Sunitinib
3
selinexor
2
perifosine
2
pembrolizumab
2
Trabectedin
2
Specimen Handling
2
Loperamide
2
Gemcitabine
2
Filgrastim
2
Dacarbazine
2
Cisplatin
2
Biopsy
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
spartalizumab
1
sargramostim
1
romidepsin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ixazomib
1
indolepropanol phosphate
1
futibatinib
1
fludarabine
1
cabozantinib
1
brostallicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Alveolar Soft Part
×
Tablets
×
Sarcoma
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled